CLINICAL STUDY PROTOCOL
XEN-45 Gel Stent Versus Trabeculecto my in Glaucoma: Gold-standard 
Pathway Study (GPS)
Protocol Number: CMO-US-EYE-[ADDRESS_170612] Number: Not Applicable
ClinicalTrials.gov Number: [STUDY_ID_REMOVED]
Syneos Health Study Number: [ADDRESS_170613]: XEN-45 Gel Stent (XEN)
Phase: Postmarketing study
Sponsor: Allergan (North America)
[ADDRESS_170614] Research Organization: Syneos Health
[ADDRESS_170615]
Morrisville, NC [ZIP_CODE]
[LOCATION_002]
Protocol Date: 21 Mar 2019
Protocol Version: Version 2.[ADDRESS_170616] party without the 
written permission of Allergan.[STUDY_ID_REMOVED]
Allergan [ADDRESS_170617] Manager
Name:
[CONTACT_1641]: , CMO Clinical Trial Manager
Address: Allergan plc
[ADDRESS_170618]
Irvine, CA [ZIP_CODE]
[LOCATION_002]
Telephone No.:
Statistician
Name:
[CONTACT_1641]: , Global Medical Operations Biostatistics
Address: Allergan
5 Giralda Farms
Madison, NJ [ZIP_CODE] 
[LOCATION_002]
Telephone No.:
Contract Research Organization Personnel
Medical Monitor   
Name:
[CONTACT_1641]:
Address: Syneos Health
Encino Trace Building II, Suite [ADDRESS_170619]
Austin, TX [ZIP_CODE] 
[LOCATION_002]
Telephone No.: Direct Mobile
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 4 of 63
CONFIDENTIAL3 SYNOPSIS
Protocol Number:
CMO-US-EYE-0600
Title:
XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-standard Pathway Study (GPS)
Study Product:
XEN-45 Gel Stent (XEN)
Study Centers:
Approximately 25 to 40 sites in the [LOCATION_002]
Phase:
Postmarketing
Objective:
To compare the effectiveness and safety of XEN to trabeculectomy in subjects with glaucoma refractory 
to topi[INVESTIGATOR_148504] (IOP) not at target on 1 or more topi[INVESTIGATOR_146934].
Study Design:
Multicenter, randomized, parallel-group, prospective, open-label
Number of Subjects: 
Eyes of approximately 285 subjects ([ADDRESS_170620]) will be randomized to have approximately 
256 study eyes complete the study.
Treatment:
XEN or Trabeculectomy
Study Duration:12 months per participating study eye
Study Methodology:
This study will include subjects with glaucoma poorly  controlled on topi[INVESTIGATOR_148505] a subconjunctival drainage procedure. Subjects will be screened for enrollment and eligible candidates 
will be approached to ascertain interest in study participation. Subjects will be randomized at a ratio of 2:1, resulting in approximately 190 eyes being implan ted with XEN and approximately 95 eyes receiving
trabeculectomy. A randomized study design was chosen because it prevents selection bias in treatment 
assignments and produces comparable groups.
Study Population:
Inclusion Criteria
To be eligible for study entry subjects must satisfy all the following criteria in the study eye (only 1 eye 
will be allowed in the study):
1.0DOHRUIHPDOHVXEMHFWVDJHV¬ï\HDUV
2. Able to provide signed written informed consent
3. Glaucoma in which the IOP is not controlled on current topi[INVESTIGATOR_15434]-lowering glaucoma 
medication
4. Best-corrected baseline Snellen visual acuity of 20/100 or better 
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 5 of 63
CONFIDENTIAL5. Visual field mean deviation no worse than -18.0 dB (with no dense paracentral scotomas, eg,
>18 dB total deviation on 1 or more of the 4 paracentral points)
6.0HGLFDWHG,23¬ï 15 mm+JDQG¬î [ADDRESS_170621] 1 topi[INVESTIGATOR_15434]-lowering medication
7. Subjects not anticipated to require any other ocular surgery (eg, cataract surgery) in either eye up 
to 3 months from the time of inclusion 
8. Area of healthy, free, and mobile conjunctiva in the target area, ie, superior bulbar conjunctiva
9. Visible trabecular meshwork with 6KDIIHUDQJOHJUDGH¬ï 2 in the target area or, in eyes with prior 
failed angle surgery, an open angle in the target area 
10. Preoperative laser trabeculoplasty is allowed 3 or more months prior to randomization 
11. Failed ab-interno canal or suprachoroidal microinvasive glaucoma surgery (MIGS) procedures 
(such as iStent¬Æ, gonioscopy-assisted transluminal trabeculotomy [GATT], ab-interno canaloplasty 
[ABiC‚Ñ¢], Kahook Dual Blade goniotomy, etc) are allowed 3 or more months before enrollment,
with the exception of CyPass¬ÆMicro-Stents, which are not allowed. Ab-interno ablative 
procedures (such as endoscopic cyclophotocoagulation [ECP]) are also allowed 3 or more months 
before enrollment.
Exclusion Criteria
Subjects will be excluded from the study if one or more of the following criteria are applicable in the 
study eye:
1. Subject has active neovascular, uveitic, or angle-recession glaucoma or any glaucoma associated 
with vascular disorders 
2. Subject has had prior ab-externo incisional glaucoma surgery (such as trabeculectomy, 
viscocanalostomy, canaloplasty, tube shunts of any type, collagen implants, etc.), conjunctival 
filtering surgery (such as XEN), transscleral cycloablative procedures (such as 
cyclophotocoagulation, micropulse cyclophotocoagulation, cryotherapy, ultrasonic circular cyclocoagulation [UC3], etc) or prior major conjunctival surgery (ie, scleral buckle)
3. Clinically significant inflammation or infection within 30 days before the Preoperative Visit (eg,
blepharitis, conjunctivitis, severe ocular surface disease, keratitis, uveitis, herpes simplex infection)
4. Presence of conjunctival scarring or prior conjunctival surgery or other conjunctival pathologies 
(eg, pterygium) in the target area
5. History of corneal surgery, corneal opacities, or corneal disease that could impact 
assessments/surgical outcomes in the study
6.&HQWUDOFRUQHDOWKLFNQHVV¬î »ùPRU¬ï 620»ùP
7. Subjects on systemic carbonic anhydrase inhibitors (eg, Diamox
¬Æ[acetazolamide] and Neptazane¬Æ
[methazolamide]) at Baseline Qualifying Visit
8. Vitreous present in the anterior chamber
9. Aphakia
10. Subject has had prior intraocular VXUJHU\LQHLWKHUH\HZLWKLQ¬î 3 months before the Preoperative
Visit (including phacoemulsification)
11. History of complicated cataract surgery with vi sual impairment, vitreous loss, anterior chamber 
intraocular lens (ACIOL), sutured intraocular lens (IOL), scleral fixated IOL or cystoid macular 
edema (CME), dislocated IOL
12. Presence of intraocular silicone oil
13. Active diabetic retinopathy, proliferative retinopathy, choroidal neovascularization, branch retinal 
vein occlusion, central retinal vein occlusion, geographic atrophy, or other ophthalmic disease or 
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 6 of 63
CONFIDENTIALdisorder that could confound study results or impaired epi[INVESTIGATOR_148506] (eg, Sturge-
Weber or nanophthalmos, Axenfeld-Rieger, iridocorneal endothelial [ICE] syndrome, etc)
14. Known or suspected allergy or sensitivity to drugs required for the protocol (including anesthesia), 
or any of the device components (eg, bovine or porcine products, or glutaraldehyde)
15. Pregnant or nursing women and those planning a pregnancy during the study period
16. Participation in another drug or device clinical trial that concludes within 30 days before the 
Preoperative Visit or that starts at any time during this study
Primary Effectiveness Endpoint:
Percentage of s XEMHFWVDFKLHYLQJ¬ïPHDQ,23UHGXFWLRQIURP baseline at Month 12 on the same or 
fewer number of topi[INVESTIGATOR_15434]-lowering medications, without clinical hypotony, loss of vision to count 
fingers, or a secondary glaucoma surgical intervention.
Secondary Endpoints:
Effectiveness:
xMean and changes in mean IOP and number of topi[INVESTIGATOR_15434]-lowering medications from 
preoperative baseline over time 
xChange from baseline (medicated) in mean IOP and mean number of topi[INVESTIGATOR_15434]-lowering medications at Month 12
xProportion of eyes achieving specific IOP targets ( ¬î18 mm Hg, ¬î17 mm Hg, ¬î16 mm Hg,
¬î15 mm Hg, ¬î14 mm Hg, ¬î13 mm Hg, and ¬î12 mm Hg at Month 12)
xProportion of eyes achieving specific percentage IOP lower targets from baseline ( ¬ï25% to 50% 
in 5% increments)
x3URSRUWLRQRIH\HVDFKLHYLQJ¬ï IOP reductions and specific IOP targets detailed above on 
same or lower number of topi[INVESTIGATOR_15434]-lowering medications at Month 12
xMean and changes in mean IOP and number of topi[INVESTIGATOR_15434]-lowering medications from 
preoperative baseline over time in eyes with medicated EDVHOLQH,23¬îPP+J
xNeedling rates; number of needlings per eye; outcomes post needling, including mean IOP and 
number of medications measured by [CONTACT_148521] >20% reduction at Month 12
on same or fewer topi[INVESTIGATOR_15434]-lowering medications, and number of subjects not using any 
topi[INVESTIGATOR_15434]-lowering medications; and antifibrotic use during needling
Complete and qualified success:
xComplete success (IOP ¬î8 mm Hg, with 20% or greater IOP lowering from medicated baseline 
on no topi[INVESTIGATOR_5910]) at Month 12 (eyes with clinical hypotony will be excluded)
xQualified success (IOP ¬î8 mmHg with 20% or greater IOP lowering from medicated baseline 
with topi[INVESTIGATOR_5910]) at Month 12 (eyes with clinical hypotony will be excluded)
xMedication-free eyes, mean IOP in this cohort, and proportion of eyes at specific IOPs 
(¬î18 mm Hg, ¬î17 mm Hg, ¬î16 mm Hg, ¬î15 mm Hg, ¬î 14 mm Hg, ¬î13 mm Hg, and ¬î 12 mm Hg 
at Month 12)
xProportion of eyes achieving specific percentage IOP lower targets from baseline ( ¬ï25% to 50% 
in 5% increments) with medication-free eyes. 
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 7 of 63
CONFIDENTIALIntraoperative adjunctive antifibrotic therapy administered: 
xCompound/product, mode of administration, dose and concentration, timing of adjunctive agent 
(surgery day and pre- and postsurgical procedure/implantation)
Visual parameters recovery post surgery:
xBest corrected visual acuity (BCVA) with current glasses (preoperative and postoperative Day 1, 
Weeks 1 and 2, and Months 1, 3, 6, 9, and 12)
xManifest refraction (baseline and postoperative Months 1, 3, 6, and 12)
xSurgically induced astigmatism (autorefractor reading [preoperative and postoperative Months 1, 6, and 12] and, at selected sites, topography [preoperative and postoperative Week 1 and 
Months 1 and 12])
xOptical biometry (anterior chamber depth and keratometric values [preoperative and 
postoperative Day 1 and Week 2]) at selected sites.
Other:
xBleb morphology (anterior segment optical coherence tomography [AS-OCT] and slit lamp 
photography at selected sites).
Safety:
xClinical hypotony defined as vision reduction (2 lines or more) related to macular changes 
consistent with hypotony maculopathy (macular folds), optic disc edema, and/or serous choroidal detachments because of low IOP
xEyes with IOP 6 mm Hg or less at any time point and relevant clinical assessment (vision 
reduction [2 lines or more] related to macular changes consistent with hypotony maculopathy
[macular folds], optic disc edema, anterior chamber status, and/or serous choroidal detachments 
because of low IOP) of these eyes at those time points
xAdverse events (AEs) including specific intraoperative and postoperative events of interest
xBCVA, pachymetry, visual field
xAE including serious AEs (SAEs)
xAdverse device effects (ADEs) including serious ADEs (SADEs)
Patient-reported Outcomes:
xPatient-reported Outcomes (PRO)
Sample Size:
The trial is intended to demonstrate that XEN is comparable to trabeculectomy in terms of treatment 
success rate. The sample size calculation is based on an equivalence test.
To control Type-I error rate at 5% and to attain 80% power for demonstrating that the difference is within 
the equivalence limit of 18%, about 256 study eyes will be needed for the study with a randomization ratio of 2:1 for the XEN arm: trabeculectomy arm. Allowing a 10% dropout rate for the first year, 
approximately 285 study eyes (190 for the XEN arm and 95 for the trabeculectomy arm) will need to be recruited for the study.
Statistical Analysis:
Four analysis populations will be used:
xEnrolled population: all study eyes for which the subject has signed the ICF
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 8 of 63
CONFIDENTIALxIntent-to-treat (ITT) population: all enrolled eyes randomized to study glaucoma surgery (XEN 
or trabeculectomy)
xModified Intent-to-treat (mITT) population: eyes in the ITT population that receive study 
glaucoma surgery and have no major protocol deviations
xSafety population: all enrolled eyes that undergo study glaucoma surgery, whether surgery is 
completed or aborted, and have follow-up visits or evaluations
The ITT population will be the primary effectiveness analysis population; some effectiveness analyses will also be run with the mITT population. All safety analyses will be run with the Safety population.Descriptive statistics (such as mean, SD, minimum, median, and maximum) will be presented for each 
continuous variable. Categorical variables will be displayed using frequency counts and percentages.
7KHQXPEHUDQGSURSRUWLRQRIVXEMHFWVDFKLHYLQJ¬ïPHDQ,23U HGXFWLRQIURPEDVHOLQHDW0RQWK
on the same or fewer number of topi[INVESTIGATOR_15434]-lowering medications, without clinical hypotony, loss of 
vision to count fingers, or a secondary glaucoma surgical intervention will be tabulated with 95% CI calculated by [CONTACT_148522]. The difference of the proportions will be estimated 
and the 95% CI of the difference will also be calculated with the method of normal approximation. The 
2 treatment arms will be claimed as equivalent if the 95% CI of the differences is within the -18% to 18% interval. The least squares mean change from baseline in IOP and the least squares mean difference between the 2 treatment groups will be estimated using the analysis of covariance (ANCOVA) model or the mixed-effect model repeat measurement (MMRM) model. The proportion and the 95% CI ofcomplete success and qualified success will be calculated with normal approximation. All reported 
treatment-emergent AEs and all safety measures collected will be tabulated by [CONTACT_33335].
Allergan [ADDRESS_170622] of Abbreviations and Definition of Terms............................................ 12  
6 Introduction .................................................................................................... 14  
6.1 Overview of Glaucoma................................................................................... 14  
6.2 XEN Gel Stent................................................................................................. 16  
6.2.1  Device Description.......................................................................... 16  
6.2.2  Clinical Experience ......................................................................... 16  
7 Study Objectives............................................................................................. 17  
7.1 Primary Endpoint........................................................................................... 17  
7.2 Secondary E ndpoints ..................................................................................... 17  
7.3 Exploratory Objective.................................................................................... 19  
8 Investigational Plan........................................................................................ 20  
8.1 Overall Study Design and Plan: Description ............................................... [ADDRESS_170623] and Procedures......................................................... 28  
[IP_ADDRESS]  XEN................................................................................................. 28  
[IP_ADDRESS]  Comparator ‚Äì Trabeculectomy........................................................ 28  
8.4.2  Packaging and Labeling .................................................................. 28  
8.4.3  Device Complaint Reporting........................................................... 28  
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 10 of 63
CONFIDENTIAL8.4.4  Method of Assigning Subjects to Treatment Groups ...................... 28  
8.4.5  Prior and Concomitant Therapy ...................................................... 29  
9 Timing of Study Procedures.......................................................................... 30  
9.1 Pretreatment Visits......................................................................................... 30  
9.1.1  Baseline Qualifying Visit ................................................................ 30  
9.1.2  Preoperative Visit (Visit 1).............................................................. 30  
9.1.3  Operative Visit (Visit 2).................................................................. 30  
9.2 Postoperative Visits ........................................................................................ 30  
9.2.1  Day 1 (Visit 3)................................................................................. 30  
9.2.2  Week 1 (Visit 4) .............................................................................. 31  
9.2.3  Week 2 (Visit 5) .............................................................................. 31  
9.2.4  Month 1 (Visit 6)............................................................................. 31  
9.2.5  Month 3 (Visit 7)............................................................................. 31  
9.2.6  Month 6 (Visit 8)............................................................................. 31  
9.2.7  Month 9 (Visit 9)............................................................................. 31  
9.2.8  Month 12 (Visit 10)......................................................................... 31  
9.2.9  Early Withdrawal Visit.................................................................... 31  
9.3 Duration of Study ........................................................................................... 31  
9.4 Pregnancy........................................................................................................ 32  
10 Effectiveness and Safety Variables ............................................................... 33  
10.1  Effectiveness and Safety Measurements Assessed....................................... 33  
10.1.1  Effectiveness Variables ................................................................... 33  
[IP_ADDRESS]  Intraocular Pressure......................................................................... 33  
[IP_ADDRESS]  Topi[INVESTIGATOR_15434]-lowering Medication................................................... 33  
[IP_ADDRESS]  Patient-reported Outcomes.............................................................. 33  
10.1.2  Safety Analysis................................................................................ 34  
[IP_ADDRESS]  Adverse Events................................................................................ [ADDRESS_170624] (18 items)
SLT selective laser trabeculoplasty
SOP standard operating procedureUC3 ultrasonic circular cyclocoagulation
WHO World Health Organization
Allergan [ADDRESS_170625] common types of glaucoma are 
primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG). 
Asia accounts for a disproportionate number of  PACG cases, whereas the prevalence of 
POAG is more evenly distri buted throughout the world ( Quigley 1996 ).
The goal in the treatment of glaucoma is to prevent further loss of functional vision 
during the remainder of a patient‚Äôs life and to avoid an a dverse impact on the patient‚Äôs 
quality of life ( AAO Glaucoma PPP Panel 2015 ).
There are many known risk factors for glau coma including age, ethnicity, and family 
history. Intraocular pressure (IOP) is the onl y modifiable risk factor that is currently 
available to arrest visual field loss and re duction of IOP has been shown to reduce the 
risk of glaucomatous visual field loss in many landmark trials.
The prevention of glaucomatous loss of vision is mainly achieved by [CONTACT_148523] a threshold that is deemed to be  safe for the ganglion cells given the current 
amount of damage in the optic nerve head (ie, target IOP).There are many approaches to lower IOP including pharmacotherapy (topi[INVESTIGATOR_148507]), laser therapy, and surgery. Topi[INVESTIGATOR_148508], especially in early disease along with selective laser trabeculoplasty (SLT).Most patients require multiple medications to lower IOP to target ( AAO Glaucoma PPP
Panel 2015 ).
Traditional incisional glaucoma surgery resu lts in robust IOP lowering; however, the 
accompanying side effects often preclude use earlier in the treatment paradigm. Trabeculectomy is the gold standard and cu rrently the most commonly used drainage 
procedure, but complications are a major problem. Early and late complications include bleb leak, excessive drainage, flat anterior chamber, filtration failure, clinical hypotony, symptomatic blebs, bleb encapsulation, f iltration failure, hyphema , choroidal effusion, 
suprachoroidal hemorrhage, and bleb infection ( Gedde et al. 2007 ). Complications 
associated with drainage surgeries can have  serious consequences and require careful 
management to prevent further problems. Th e bleb is currently the cornerstone of 
trabeculectomy drainage surgery, but the trabeculectomy bleb is also fragile and 
susceptible to scarring ( Azuara-Blanco and Katz 1998 ). Another subconjunctival 
surgical approach includes the Ex-PRESS
¬Æminiature glaucoma implant (Alcon 
Laboratories Inc., Fort Worth, TX), which is a biocompatible, nonvalved stainless steel 
tube. The Ex-PRESS is currently implanted using a procedure like standard trabeculectomy, and includes creation of a scle ra flap and a conjunc tival filtration bleb, 
but no peripheral iridectomy is requi red when implanting the Ex-PRESS ( Moisseiev et 
al. 2015).
Allergan [ADDRESS_170626] an important role in glaucoma 
management, offering the ability to achieve IOP lowering independent of patients‚Äô 
compliance in appropriate candidates. Tube shunts are being increasingly used in the 
surgical management of glaucoma. The Ahmed glaucoma valve and the Baerveldt 
implant represent the most commonly used tube shunts. The Ahmed valve has a valve 
mechanism to prevent postoperative hypotony and shallow anterior chambers, whereasthe Baerveldt implants provide a greater su rface area in the end plate for aqueous 
reabsorption, providing better IOP control and a reduced need for glaucoma medication 
over the long term ( Gedde et al. 2010, Wang et al. 2016 ). All the above procedures,
performed using an ab-externo approach, achieve lowering of IOP via drainage of 
aqueous from the anterior chamber to the subconjunctival space ( Gedde et al. 2012).
However, each of these procedures is associated with a lengthy and variable recuperation and prolonged time to visual recovery. In some instances, there is associated loss of best corrected visual acui ty (BCVA) and significant risk of short- and 
long-term complications, including hypotony, choroidal effusion, cataract, and flat or 
shallow anterior chamber, as well as valve-re lated complications, such as tube blockage, 
erosion, and endothelial cell loss ( Gedde et al. 2012, Shaarawy et al. 2004, Rulli et al.
2013, Vijaya et al. 2011 ).
An alternative option to the more invasive traditional surgeries described above, in the 
form of microinvasive glaucoma surgery (MIGS) devices, are now available that have
an improved safety profile and recovery compared with trabeculectomy and tube shunts(Saheb and Ahmed 2012 ). There are several devices fitting the definition of MIGS
including XEN-45 Gel Stent (XEN); they can be categorized by [CONTACT_148524], ie, they may improve outflow by [CONTACT_148525] ( Caprioli et al. 2015 ). Unlike canal-based and 
supraciliary MIGS devices, XEN facilitates subconjunctival drainage like the gold-standard surgical option trabeculectomy to provide robust IOP lowering from a medicated baseline ( Vera et al. 2018, Mansouri et al. 2018, Hengerer et al. 2017 ).
Topi[INVESTIGATOR_148509]-angle glaucoma. Although the standard practice is  to prescribe a second IOP-lowering 
medication when the first drug has lowered a patient‚Äôs IOP, but not to an optimal level, the efficacy seen with monotherapy may not  translate into similar efficacy when a 
medication is used adjunctively. Additionally, the side effects of multiple medications need to be considered fo r patient quality of life ( Fechtner and Singh 2001 ). 
To quantify the IOP reduction after surgery in clinical trials versus topi[INVESTIGATOR_15434]-lowering medications, a consistent definition of the ba seline, or reference IOP is necessary. For 
practical purposes, the highest challenge for a trial is the maximal tolerated medical therapy (MTMT) of IOP-lowering medications because that level would be considered the best that those drugs can achieve ( Shaarawy et al. 2004) . To determine the MTMT 
for glaucoma and the amount of medication an  eye can tolerate, patients may need to 
endure severe adverse effects before advancin g to surgery. In contrast, in clinical 
practice, the goal is optimal medical therapy, in which the practitioner uses the least amount of medicine to achieve the desired goal with the least adverse effects. In 
Allergan [ADDRESS_170627] medicati on is added, it is unlikely that additional 
agents will improve the outcome ( Fechtner and Singh 2001).
6.2 XEN Gel Stent
6.2.1 Device Description
A MIGS drainage device implanted via an ab-interno approach that facilitates drainage 
of aqueous from the anterior chamber to th e subconjunctival space (XEN-45; Allergan, 
Irvine, CA) has recently been approved in  the [LOCATION_002] for use in the surgical 
management of glaucoma. This device, whic h can be used as a standalone procedure, 
offers the potential to achieve IOP lowering that is comparable to trabeculectomy, butwith less tissue manipulation ( Schlenker et al. 2017, Reitsamer 2016 ).
The device, which is implanted using a handhe ld disposable injector, is constructed 
from porcine-derived gelatin that is formed into a tube and cross-linked with glutaraldehyde, thus allowing it to expa nd and remain flexible when hydrated. The 
expansion of the tube‚Äôs outer diameter, when in contact [CONTACT_148526], also aids in retention 
of the gel stent in its inte nded location after surgical imp lantation, which helps minimize 
many of the issues associated with other materials, such as migration, erosion, andcorneal endothelial damage ( Aref and Varma 2012 ). The gel stent was designed using 
principles established by [CONTACT_148527]‚ÄìPoiseu ille equation, whereby [CONTACT_148528] e length of the tube, and decreases to the 
fourth power of the diameter of the tube  lumen. In sum, a longer and thinner tube 
provides greater resistance than a shorter and wider tube ( Sheybani et al. 2015 ).
The XEN Gel Stent, XEN-45, or XEN Ge l Implant (XEN) is indicated for the 
management of refractory glaucomas, incl uding cases in which previous surgical 
treatment has failed, cases of POAG, and ca ses of pseudoexfolia tive or pi[INVESTIGATOR_148510].
6.2.[ADDRESS_170628] shown XEN is effective at reducing IO P with fewer complications as compared 
with those published for trabeculectomy studies ( Schlenker et al. 2017, Mansouri et al. 
2018, Hengerer et al. 2017, DeGregorio et al. 2018, Grover et al. 2017) .
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 17 of 63
CONFIDENTIAL7 STUDY OBJECTIVES
To compare the effectiveness and safety of XEN to trabeculectomy in subjects with 
glaucoma refractory to topi[INVESTIGATOR_148504] (IOP) not at target on 1 or more topi[INVESTIGATOR_5910].
7.1 Primary Endpoint
3HUFHQWDJHRIVXEMHFWVDFKLHYLQ J¬ïPHDQ,23UHGXFWLRQIUR m baseline at Month 12 
on the same or fewer number of topi[INVESTIGATOR_148511] P-lowering medications, without clinical 
hypotony, loss of vision to count fingers, or  secondary glaucoma surgical intervention.
7.2 Secondary EndpointsEffectiveness:
xMean and changes in mean IOP and number of topi[INVESTIGATOR_15434]-lowering 
medications from preoperative baseline over time
xChange from baseline (medicated) in mean IOP and mean number of topi[INVESTIGATOR_15434]-lowering medications at Month 12
x3URSRUWLRQRIH\HVDFKLHYLQJVSHFLILF,23WDUJHWV¬îPP +J¬î mm Hg, 
¬îmm+J¬îPP +J¬îPP +J¬îPP Hg, and ¬îPP Hg at 
Month 12)
xProportion of eyes achieving specific  percentage IOP lower targets from 
EDVHOLQH¬ï % to 50% in 5% increments)
x3URSRUWLRQRIH\HVDFKLHYLQJ¬ï ,23UHGXFWLRQVDQGVSHFLILF, 23WDUJHWV
detailed above on same  or lower number of topi[INVESTIGATOR_15434]-lowering medications at 
Month 12 
xMean and changes in mean IOP and number of topi[INVESTIGATOR_15434]-lowering medications from preoperative baseline over time in eyes with medicated 
EDVHOLQH,23¬î mm Hg
xNeedling rates; number of needlings per eye; outcomes post needling, including 
mean IOP and number of medications measured by [CONTACT_148521] 
>20% reduction at Month 12 on same  or fewer topi[INVESTIGATOR_15434]-lowering 
medications, and number of subjects not using any topi[INVESTIGATOR_15434]-lowering 
medications; and antifibrotic use during needling.
Complete and qualified success:
x&RPSOHWHVXFFHVV,23¬î mm Hg, with 20% or greater IOP lowering from 
medicated baseline on no topi[INVESTIGATOR_148512]) at Month 12 (eyes with clinical 
hypotony will be excluded)
x4XDOLILHGVXFFHVV,23¬î mm Hg with 20% or greater IOP lowering from 
medicated baseline with topi[INVESTIGATOR_148512]) at Month 12 (eyes with clinical 
hypotony will be excluded)
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 18 of 63
CONFIDENTIALxMedication-free eyes, mean IOP in this cohort, and proportion of eyes at specific 
IOPs (¬î18 mm Hg, ¬î17 mm Hg, ¬î16 mm Hg, ¬î15 mm Hg, ¬î 14 mm Hg, 
¬î13 mm Hg, and ¬î12 mm Hg at Month 12) 
xProportion of eyes achieving specific percentage IOP lower targets from 
EDVHOLQH¬ï % to 50% in 5% increments) with medication-free eyes. 
Intraoperative adjunctive antifibrotic therapy administered: 
xCompound/product, mode of administra tion, dose and concentration, timing of 
adjunctive agent (surgery day and pre- and postsurgical procedure/implantation).
Visual parameters recovery post surgery:
xBCVA with current glasses (preoperative and postoperative Day 1; Weeks 1 and
2; and Months 1, 3, 6, 9, and 12) 
xManifest refraction (baseline a nd postoperative Months 1, 3, 6, and 12)
xSurgically induced astigmatism (aut orefractor reading [preoperative and 
postoperative Months 1, 6, and 12] and, at selected sites, topography [preoperative and postoperative Week 1, and Months 1 and 12])
xOptical biometry (anter ior chamber depth and keratometric values) at 
preoperative and postoperative Day 1 and Week 2 at selected sites.
Other:
xBleb morphology (anterior segment optical coherence tomography [AS-OCT]
and slit lamp photography at selected sites).
Safety:
xClinical hypotony defined as vision re duction (2 lines or more) related to 
macular changes consistent with hypotony maculopathy (macular folds), optic 
disc edema, and/or serous choroi dal detachments because of low IOP
xEyes with IOP 6 mm Hg or less at any time point and relevant clinical assessment (vision reduction [2 lines or  more] related to macular changes 
consistent with hypotony maculopathy [macular folds], optic disc edema, 
anterior chamber status, and/or serous  choroidal detachments because of low 
IOP) of these eyes at those time points 
xAdverse events (AEs) including specific intraoperative and postoperative events of interest
xBCVA, pachymetry, visual field 
xAEs including serious AEs (SAEs)
xAdverse device effects (ADEs) including serious ADEs (SADEs)
Patient-reported Outcomes:
xPatient-reported Outcomes (PRO)
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 19 of 63
CONFIDENTIAL7.3 Exploratory Objective
Not applicable.
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 20 of 63
CONFIDENTIAL8 INVESTIGATIONAL PLAN
8.1 Overall Study Design and Plan: Description
This is a multicenter, randomized, parallel-group, prospective,  open-label clinical trial 
to compare the ability of XEN and trabeculectomy to reduce IOP and reduce the number
of topi[INVESTIGATOR_15434]-lowering medications in s ubjects with IOP that is poorly controlled on 
topi[INVESTIGATOR_8588].
Subjects will be randomized 2:1, resulting in approximately [ADDRESS_170629] meet the study entry criteria, the study eye will be selected by 
[CONTACT_093].
8.1.1 Study Design
Figure 8-1 Flow Chart of the Study
8.1.2 Schedule of Assessments
The schedule of planned stud y assessments is shown in Table 8.1.
Randomized 2:1
N=285
XEN
N=190
Trabeculectomy 
N=95
Screened
N=318
Note: These numbers are approximate. 
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 22 of 63
CONFIDENTIALProcedure / Data to be RecordedBaseline
Qualifying
VisitaPreoperative
Visit 1aOperative Postoperative Visits (visit window; time since Day 0)
Visit 2
Day 0Visit 3
Day 1
(6-48 h)Visit 4
Week 1
(3-10 d)Visit 5
Week 2
(11-20 d)Visit 6
Month 1
(3-8 wk)Visit 7
Month 3
(9-17 wk)Visit 8
Month 6
(18-32 wk)Visit 9
Month 9
(33-47 wk)Visit 10
Month 12
(48-60 wk)
Record Needling and Laser Suture
Lysis, and Antifibrotic TreatmentsX X X X X X X X
Adverse Events Assessment X XhXXXXXXXX
AS-OCT = anterior segment optical coherence tomography; BCVA = Best corrected visual acuity; d = day; h = hour; HIPAA = Health Ins urance Portability and 
Accountability Act; IOP = intraocular pressure; PRO = patient reported outcome; SHPC-18 = Symptom and Health Problem Checklist; w k = week; WPAI = Work 
Productivity and Activity Impairment
aThe Baseline Qualifying Visit and the Preoperative Visit may be done on the same day if there are no changes in preoperative IOP medications. The Preoperative Visit may 
be repeated to complete all procedures, if needed. The visit window for Preoperative Visit 1 (including any repeated visits) is up to 4 weeks before study glaucoma 
VXUJHU\LQWKHVWXG\H\HDQG¬ï [ADDRESS_170630] has taken IOP medication.
cBCVA should be performed using a Snellen chart with glasses.
dPerformed at Baseline Qualifying Visit and then at other times at the investigator¬¥s discretion
eCan use valid results up to 3 months prior to screening
fAt selected sites only
gPatient questionnaires should be self-administered prior to any clinical assessments.
hRefers to intraoperative events or surgical complications
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 23 of 63
CONFIDENTIAL8.2 Discussion of Study Design
8.2.1 Study Design
Subjects will be randomized at a ratio of 2:1, resulting in approxima tely [ADDRESS_170631] in study participation. 
Subjects can be enrolled into one of the following groups:
Group 1: XEN implanted (XEN group)Group 2: Trabeculectomy (Trab group).All inclusion/exclusion criteria, effectiveness endpoints, success rate determinations,
and follow-up examinations will be identical for both groups.
At baseline, subjects with glaucoma not at target IOP when using at least [ADDRESS_170632] is determined to be eligible for participation in the study and is enrolled, the physician may stop the previously prescrib ed medications 1 to 4 weeks before surgery 
and begin preoperative medications (eg, ster oids, antibiotics, artificial tears, oral 
carbonic anhydrase inhibitors [CAIs]) to prepare the ocular surface before surgery. The 
detection and treatment of co morbid conditions, particular ly diseases of the ocular 
surface disease (dry eye) and blepharitis, can help reduce eye inflammation ( Baudouin 
2012). Stoppi[INVESTIGATOR_148513]-lowering medications and replacing them, if 
necessary, with oral acetazolamide prior to surgery may be considered along with use of topi[INVESTIGATOR_148514]-free lubricants to reduce ocular surface inflammation
and improve the likelihood of  successful implantation ( Vera et al. 2018 ). 
Subjects will undergo at least 1 preoperative visit (and more as needed), and then be 
scheduled for XEN gel stent implantation or trabeculectomy. Subjects will be examined 
postoperatively at the following timepoints: Day 1; Weeks 1 and 2; and Months 1,Month 3, Month 6, Month 9, and Month 12.
8.2.2 Quality Management and Risk Evaluation
As noted in XEN‚Äôs Directions for Use the co mplications that may occur in conjunction 
with the use of XEN include, but are not limited to, the following: choroidal effusion, 
hyphema, hypotony, implant migration, imp lant exposure, wound leak, need for 
secondary surgical intervention and other known complications of intraocular surgery 
(eg, flat or shallow chamber, corneal edema, endophthalmitis).
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 24 of 63
CONFIDENTIALThe risk profile for XEN has been establis hed based on the review of all applicable 
safety data. These complicati ons include adverse reaction to  implant material, infection, 
implant failure, device malfunction, hypotony, flat anterior chamber (central lens, 
corneal touch), endophthalmitis, and ocular inju ry (inadvertent perforation of the sclera, 
hyphema, inadvertent loss of vitreous, choroidal hemorrhage or effusion, bleeding, 
device wound dehiscence). Risks involved in the procedure include persistent 
inflammation, corneal complications, retinal  complications, chor oidal complications, 
visual acuity loss (loss of 2 Snellen lines or more), chronic pain, unplanned secondary 
surgical intervention, loss of eye, and infection.
XEN is currently contraindicated under the following circumstances or conditions: 
angle-closure glaucoma, previous glaucoma shunt/valve in the target quadrant, presence 
of conjunctival scarring, prio r conjunctival surgery or ot her conjunctival pathologies 
(eg, pterygium) in the target quadrant, active inflammation (eg, blepharitis, 
conjunctivitis, keratitis, uveitis), active iris neovascularization or neovascularization of the iris within 6 months of the surgical date, anterior chamber intraocular lens (ACIOL),presence of intraocular silicone oil, vitr eous present in the anterior chamber. The 
exclusion criteria of this trial are in accord ance with the contrai ndications for the device 
(see Section 8.3.3).
The risks associated with the use of XEN are considered reasonable in comparison withthe anticipated benefits to subjects. XEN poses an acceptable level of risk for its 
intended use.
The risks associated with the gold-standard subconjunctival filtering procedure 
trabeculectomy have been well studied a nd include choroidal effusion, shallow/flat
anterior chamber, wound leak, hyphema, dyse sthesia, encapsulated bleb, and persistent 
corneal edema ( Gedde et al. 2007).
8.[ADDRESS_170633]‚Äôs eligibility should be 
discussed with the sponsor prior to enrollment.
This study plans to enroll subjects at approximately 25 to 40 sites in the [LOCATION_002].
A total of approximately 285 subjects will be included in the study: approximately [ADDRESS_170634] will be enrolled into the study. Th is includes an estimated 10% dropout rate 
after screening (see Section 11.2 for the calculation of sample size).
Allergan [ADDRESS_170635] satisfy all of the following criteria in the 
study eye (only 1 eye will be allowed in the study):
1.0DOHRUIHPDOHVXEMHFWVDJHV¬ï\HDUV
2. Able to provide signed written informed consent
3. Glaucoma in which the IOP is not c ontrolled on current topi[INVESTIGATOR_15434]-lowering 
glaucoma medication
4. Best-corrected baseline Snellen visual acuity of 20/100 or better 
5. Visual field mean deviation no worse than -18.0 dB (with no dense paracentral 
scotomas, eg, >18 dB total deviation on 1 or more of the 4 paracentral points)
6.0HGLFDWHG,23¬ï 15 mm+JDQG¬îPP Hg on at least 1 topi[INVESTIGATOR_15434]-lowering 
medication
7. Subjects not anticipated to require any other ocular surgery (eg, cataract surgery) 
in either eye up to 3 months from the time of inclusion 
8. Area of healthy, free, and mobile conjunctiv a in the target area, ie, superior bulbar 
conjunctiva
9. Visible trabecular meshwork with 6KDIIHUDQJOHJUDGH¬ïLQWKHWDUJHWDUHD or, in 
eyes with prior failed angle surgery, an open angle in the target area
10. Preoperative laser trabeculoplasty is allowed 3 or more months prior to 
randomization 
11. Failed ab-interno canal or suprachoroidal MIGS procedures (such as i-Stent¬Æ,
gonioscopy-assisted transluminal trabeculotomy [GATT], ab-interno canaloplasty 
[ABiC‚Ñ¢], Kahook Dual Blade goniotomy, etc) are allowed 3 or more months before enrollment, with the exception of CyPass
¬ÆMicro-Stents, which are not 
allowed. Ab-interno ablative procedur es (such as endoscopic cyclophoto-
coagulation [ECP]) are also allowed 3 or more months before enrollment.
8.3.3 Exclusion Criteria 
Subjects will be excluded from the study if 1 or more of the following criteria are 
applicable in the study eye:
1. Subject has active neovascular, uveitic or angle-recession glaucoma or any 
glaucoma associated with vascular disorders 
2. Subject has had prior ab-externo inc isional glaucoma surgery (such as 
trabeculectomy, viscocanalostomy, canalopl asty, tube shunts of any type, collagen 
implants, etc), conjunctival filtering surgery (such as XEN), transscleral 
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 26 of 63
CONFIDENTIALcycloablative procedures (such as  cyclophotocoagulation, micropulse 
cyclophotocoagulation, cryotherapy, ultrasonic circular cyclocoagulation [UC3],
etc) or prior major conjunctiv al surgery (ie, scleral buckle)
3. Clinically significant inflammation or infection within 30 days before the 
Preoperative Visit (eg, blepharitis, conjunctivitis, severe ocular surface disease, keratitis, uveitis, herpes simplex infection)
4. Presence of conjunctival scarring or  prior conjunctival surgery or other 
conjunctival pathologies (eg, pterygium) in the target area
5. History of corneal surgery, corneal opaci ties, or corneal dis ease that could impact 
assessments/surgical outcomes in the study
6.&HQWUDOFRUQHDOWKLFNQHVV¬î»ùPRU¬ï»ùP
7. Subjects on systemic CAIs (eg, Diamox
¬Æ[acetazolamide] and Neptazane¬Æ
[methazolamide]) at Baseline Qualifying Visit
8. Vitreous present in the anterior chamber
9. Aphakia 10.6XEMHFWKDVKDGSULRULQWUDRFXODUVXUJHU\LQHLWKHUH\HZLWKLQ ¬î3 months before 
the Preoperative Visit (inc luding phacoemulsification)
11. History of complicated cataract surgery with: visual impairment, vitreous loss, 
ACIOL, sutured intraocular lens (IOL), scleral fixated IOL or cystoid macular 
edema (CME), dislocated IOL
12. Presence of intraocular silicone oil
13. Active diabetic retinopathy, prolifer ative retinopathy, choroidal 
neovascularization, branch re tinal vein occlusion, central retinal vein occlusion, 
geographic atrophy, or other ophthalmic disease or disorder that could confound 
study results or impaired epi[INVESTIGATOR_148515] (eg, Sturge-Weber or 
nanophthalmos, Axenfeld-Riege r, iridocorneal endothelial [ICE] syndrome, etc)
14. Known or suspected allergy or sensitivity to drugs required for the protocol 
(including anesthesia), or any of the de vice components (eg, bovine or porcine 
products, or glutaraldehyde)
15. Pregnant or nursing women and those planning a pregnancy during the study 
period
16. Participation in anot her drug or device clinical tr ial that concludes within [ADDRESS_170636] Exit Form in the electronic data capture (EDC) system, indicating the early termination reason.
Subjects may withdraw their consent to continue in the study at any time. Subjects
withdrawing from the study after receiving XEN or undergoing trabeculectomy will be encouraged to complete the same final evaluations as subjects completing the study according to this protocol, particularly safety evaluations. The aim is to record data in the same way as for subjects who complete d the study. Subjects who discontinue before 
undergoing a study surgery will not be required to return for study follow-up visits.
Reasonable efforts will be made to contac t subjects who are lost to follow-up. These
efforts must be documente d in the subject‚Äôs file. 
The sponsor has the right to terminate the study at any time, in case of SAEs, or if 
special circumstances concerning the study product or the company itself occur, making 
further treatment of subjects impossible. In  this event, the investigator(s) will be 
informed of the reason for study termination.
Allergan [ADDRESS_170637] and Procedures8.4.1.1 XEN
XEN is manufactured by [CONTACT_78562], Plc (Irela nd). XEN is composed of a gelatin derived 
from porcine dermis, formed into a tube, a nd cross-linked with glutaraldehyde. It is 
intended to be inserted in the angle and th rough the sclera, connecting the anterior 
chamber to the subconjunctival space. XEN is preloaded in the XEN Injector, a single-
use mechanical delivery system. XEN is pack aged with directions for use and the 
procedure to insert XEN should be carried out in  line with surgical training provided by 
[CONTACT_148529].
[IP_ADDRESS] Comparator ‚Äì Trabeculectomy
Trabeculectomy will be performed in accordance with the standard of care at each 
investigative center with adjunctive antifibrotic therapy and including essential steps: conjunctival flap, scleral fl ap, and sclerostomy. Note: Peripheral iridectomy is not 
mandated and is left to the st andard practice of the surgeon.
8.4.2 Packaging and Labeling
XEN used will be commercial supply of XEN-45 Gel Stent in the [LOCATION_002].
8.4.3 Device Complaint Reporting
Device complaints and malfunctions should be  reported per the package insert or 
directions for use.
8.4.4 Method of Assigning Subjects to Treatment Groups
Subjects will be randomized by [CONTACT_148530] a 2:1 (XEN:trabeculectomy) 
randomization schedule by [CONTACT_148531] (Randomization and Trial Supply 
Management) application. Th e randomization list will be generated by [CONTACT_456]‚Äôs 
independent Randomiza tion Services Group using a customized validated system 
composed of a series of SAS
¬ÆMacros (version 1.4). This list will be provided to the 
contract research organization‚Äôs (CRO‚Äôs ) independent randomization team, who will 
upload the list into the Medidata Rave RTSM application and validate it. Upon 
completion of a randomization electronic case repo rt form (eCRF), indicating that a
study eye meets all entry criteria, the data will be sent to the RTSM system for randomization. The RTSM system will then provide the surgery group assignment for 
the study eye and integrate it back into the randomization eCRF. The sponsor‚Äôs and 
CRO‚Äôs study team members, inves tigational site staff, and subjects will not have access 
to the randomization list.
Allergan [ADDRESS_170638] opped 1 to 4 weeks before surgery and re-
started according to the investigator‚Äôs reco mmendation. At baseline, subjects are to be 
using at least [ADDRESS_170639] is determined to 
be eligible for participation in the study and is enrolled, the physician may stop the previously prescribed medications 1 to 4 w eeks before surgery and begin preoperative 
medications (eg, steroids, antibiotics, artificial tears) to prepare the ocular surface before surgery. The detection and treatment of como rbid conditions, particularly diseases of 
the ocular surface disease (dry eye) and bl epharitis, can help reduce eye inflammation 
(Baudouin 2012 ). Stoppi[INVESTIGATOR_148513]-lowering  medications and replacing them, 
if necessary, with oral acetazolamide prior to  surgery may be considered along with use 
of topi[INVESTIGATOR_148516]-fr ee lubricants to reduce ocular surface 
inflammation and improve  the likelihood of succ essful implantation ( Vera et al. 2018 ). 
Subjects who have had prior ab-externo in cisional glaucoma surgery (such as 
trabeculectomy, viscocanalostomy, canalopl asty, tube shunts of any type, collagen 
implants, etc), conjunctival filtering surgery (such as XEN), transscleral cycloablative procedures (such as cyclophotocoagu lation, micropulse cyclophotocoagulation, 
cryotherapy, UC3, etc) or prior major conjun ctival surgery (ie, scleral buckle) are not 
eligible for the study (see Section 8.3.3).
Perioperative adjunctive antifibrotic therap y should be used according to physician 
training and practice.
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 30 of 63
CONFIDENTIAL9 TIMING OF STUDY PROCEDURES
The planned study assessments are in Section 8.1.2 .
Every attempt should be made to schedule the visits (specifically measurement of IOP) 
at approximately the same time of day to avoid the influence of diurnal fluctuations.
Assess IOP using Goldmann applanation tonom etry. Take [ADDRESS_170640] measurement. Use the 
average if 2 measurements are taken (or the median if 3 measurements are taken) to determine each day‚Äôs IOP.
9.1 Pretreatment Visits
9.1.1 Baseline Qualifying Visit
During the study Baseline Qualifying Visit, the procedures will be performed following 
the Schedule of Assessments (Table 8.1 ).
When these procedures have been performed, the next visit will be scheduled. The Baseline Qualifying Visit and Preoperative Visit may occur on the same day if there are no changes to the IOP-lowering medications prior to surgery.
9.1.2 Preoperative Visit (Visit 1)
During the study Preoperative Visit, the procedures will be performed as shown on the 
Schedule of Assessments (Table 8.1).
This visit may be repeated as necessary to complete required examinations. The visit 
window for Preoperative Visit 1 (including any repeated visits) is up to 4 weeks before VWXG\JODXFRPDVXUJHU\LQWKHVWXG\H\HDQG¬ï [ADDRESS_170641] been pe rformed, if all entry 
criteria are met, the study eye will be rando mized to glaucoma surgery procedure, and 
the next visit will be scheduled.
9.1.3 Operative Visit (Visit 2)
The Operative Visit (Visit 2) will be Day 0 of the study. At this visit, glaucoma surgery 
(XEN or trabeculectomy) will be performed. Record any intraoperative complications.
9.2 Postoperative Visits
9.2.1 Day 1 (Visit 3)
The first postoperative visit will take place on study Day 1 (6-48 hours) after the 
Operative Visit. During this visit the procedures will be performed following the Schedule of Assessments (Table 8.1).
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 31 of 63
CONFIDENTIAL9.2.2 Week 1 (Visit 4)
Visit [ADDRESS_170642] 1 week (3-10 days) after the Operative Visit. During this visit the 
procedures will be performed following the Schedule of Assessments ( Table 8.1 ).
9.2.3 Week 2 (Visit 5)Visit [ADDRESS_170643] 2 weeks (11-20 days) after the Operative Visit. During this visit 
the procedures will be performed following  the Schedule of Assessments (Table 8.1).
9.2.4 Month 1 (Visit 6)
Visit [ADDRESS_170644] 1 month (3-8 weeks) after the Operative Visit. During this visit 
the procedures will be performed following  the Schedule of Assessments (Table 8.1).
9.2.5 Month 3 (Visit 7)Visit [ADDRESS_170645] 3 months (9-17 weeks) after  the Operative Visit. During this visit 
the procedures will be performed following  the Schedule of Assessments (Table 8.1).
9.2.6 Month 6 (Visit 8)Visit [ADDRESS_170646] 6 months (18-32 weeks) af ter the Operative Visit. During this 
visit the procedures will be performed following the Schedule of Assessments
(Table 8.1).
9.2.7 Month 9 (Visit 9)
Visit [ADDRESS_170647] 9 months (33-47 weeks) af ter the Operative Visit. During this 
visit the procedures will be performed following the Schedule of Assessments
(Table 8.1).
9.2.8 Month 12 (Visit 10)
Visit [ADDRESS_170648] 12 months (48-60 weeks) after the Operative Visit. During this 
visit the procedures will be performed following the Schedule of Assessments
(Table 8.1).
9.2.[ADDRESS_170649] becomes pregnant during the study, the investigator will notify 
Allergan immediately by [CONTACT_148532] +[PHONE_3310] or +[PHONE_3311]. Best 
practices are to be followed to ensure the welfare of the subject and the fetus. Once the pregnancy has reached term, the second page of the Pregnanc y Surveillance Form 
concerning outcome is to be completed. The medical safety physician will contact [CONTACT_148533]. The subject will 
continue to be followed up as part of the implanted population. Pregnancy by [CONTACT_148534]. Hosp italization for a normal delivery or elective 
abortion of a normal fetus does not constitute an SAE. However, the occurrence of an adverse pregnancy outcome for the mother or child may constitute an AE or SAE, and these are to be reported. 
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 33 of 63
CONFIDENTIAL10 EFFECTIVENESS AND SAFETY VARIABLES
10.1 Effectiveness and Safety Measurements Assessed10.1.1 Effectiveness Variables10.1.1.1 Intraocular Pressure
Every attempt should be made to schedule the visits at a pproximately the same time of 
day to avoid the influence of diurnal fluc tuations on study procedures, specifically 
measurement of IOP.
Except at the Operative Visit (Visit 2), IOP will be measured at all study visits by 
[CONTACT_148535]. T he readings will be recorded on the 
appropriate eCRF. The tonomet er should be checked for proper calibration monthly and 
the date of calibration checking should be recorded. The eye cannot have received pupil-dilating medications. 
[IP_ADDRESS] Topi[INVESTIGATOR_15434]-lowering Medication
For endpoints evaluating the number of topi[INVESTIGATOR_148517]-lowering medications taken by [CONTACT_1560], the following are examples of the classes of medications to be recorded: 
prostaglandin analogues, beta-adrenergic an tagonists, CAIs, alpha-adrenergic agonists, 
pi[INVESTIGATOR_1227], and combinati ons of these treatments.
[IP_ADDRESS] Patient-reported OutcomesThe following [ADDRESS_170650] status.
Questionnaires will be administered to subj ects on an electronic ta blet at the visits 
designated in Table 8.1 . Data from completed questionnair es will be imported into the 
eCRF using a validated process.
1. Collaborative Initial Glaucoma Treatment Study (CIGTS) Symptom and
Health Problem Checklist (SHPC-18)
2. Postsurgical question on resumption of activities and daily routine
3. Work Productivity and Activity Impa irment (WPAI): Productivity outcomes.
The SHPC-18 is an18-item questionnaire that asks subjects being treated for glaucoma 
questions about eye symptoms or problem s they may experience. The questionnaire 
includes 2 domains: local eye symptoms (7 items) and visual function problems 
(11 items). The development of the SHPC-[ADDRESS_170651] 7 days. If the subjec t responds ‚ÄúYes‚Äù, they are then asked how 
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 34 of 63
CONFIDENTIALburdensome the symptom or problem was, w ith Likert-type response options ranging 
from ‚ÄúNot at all‚Äù to ‚ÄúA lot‚Äù ( Musch et al. 2017 ). 
The WPAI is included because overall work productivity is significantly related to 
general health perceptions and the global measures of interference with regular activity (Reilly et al. 1993 ).
Additionally, responses to the Postsurgi cal Question will be collected to better 
understand differences, if any, in postoperative recovery between the 2 procedures.
These measures can be found in Appendix 17 .
10.1.2 Safety Analysis
Safety analysis will be performed in  both the XEN population and the population 
randomized to trabeculectomy. The numbers and percentage of subjects reporting AEs 
will be tabulated regardless of causality. AEs, ADEs, and all safety measures will be 
summarized by [CONTACT_148536].
[IP_ADDRESS] Adverse Events
Throughout the course of the study, all AE s will be monitored and reported on an AE 
eCRF, including seriousness, severity, action taken, and relationship to study treatment. 
If AEs occur, the first concern will be the safety of the study participants. Needling and 
laser suture lysis will be captured as procedures but will not be considered AEs.
All AEs and device deficiencies that occur be tween visits are to be recorded on the date 
of the next postoperative exa mination on the subject‚Äôs eCRF.
[IP_ADDRESS].1 Definitions
The investigators will classify the AEs based on the following definitions according to 
ISO [ZIP_CODE] (2011).
Adverse Event
An AE is defined in accordance with ISO [ADDRESS_170652] c linical signs (including abnormal laboratory 
findings) in subjects, users or other persons , if related to the investigational medical 
device. This definition includes events relate d to the investigational medical device or 
comparator and events related to the pro cedures involved. Disease signs and symptoms 
that existed prior to the study treatment are not considered AEs unless the condition recurs after the participant has recovered from the pre-existing condition or the condition worsens in intensity or frequency during the study.
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 35 of 63
CONFIDENTIALAEs will be monitored throughout the study beginning with the Preoperative Visit. At 
each postbaseline visit, the investigator will begin querying for AEs by [CONTACT_148537] a general, nondirected question such as ‚ÄúHave you had any changes to your condition since your last visit?‚Äù Previous AEs and changes in therapy/concomitant medications are to be updated. Directed que stioning and examination will then be done 
as appropriate. All reportabl e AEs and clinically signif icant abnormal laboratory 
findings will be documented on the appropriate eCRF.
Adverse Device Effect (ADE)
An ADE is defined in accordance with ISO [ZIP_CODE] as ‚Äúan adverse event related to the 
use of an investigational medical device.‚Äù This definition includes any AEs resulting from insufficient or inadequate instruc tions for use, deployment, implantation, 
installation, or operati on, or any malfunction of the inve stigational medical device as 
well as any event resulting from use error (per ISO [ZIP_CODE]) or from intentional misuse of 
the investigational medical device. 
Device Deficiency or Complaints
A device deficiency is defined in acco rdance with ISO [ADDRESS_170653] led to the
SADE. These shall be reported to the regulatory authorities and independent ethics committees/institutional review boards (IECs/IRBs) as required by [CONTACT_94097].
[IP_ADDRESS].[ADDRESS_170654] of AEs that can occur intraoperatively during implantation of 
XEN and/or trabeculectomy surgery. These and any other AEs that occur should be reported in the AE eCRF:
xDetached Descemet‚Äôs membrane
xIris damage
xLens contact
[CONTACT_148538] [ADDRESS_170655] of AEs that can occur postoperatively for XEN and/or 
trabeculectomy surgery. These and any other AEs that occur should be reported in the 
AE eCRF:
xAngle recession
xAnterior chamber shallow with peripheral iridocorneal touch
xAnterior chamber flat w ith iridocorneal touch
xBCVA loss of ¬ï2 lines (¬ïEarly Treatment Diabe tic Retinopathy Study 
[ETDRS] letters)
o¬îGD\V
o>30 days
oAt 12 months (persistent loss)
xBleb leak (without operative room or slit lamp revision)
xBleb leak (with operative room or slit lamp revision)
xBlebitis (with or without anterior  chamber reaction or hypopyon) 
xCataract formation
xClinically significant progression of cataract, based on an assessment by [CONTACT_148539] (extending poste rior to equator, without blood)
xChoroidal effusion (obscuring disc or macula, without blood)
xChoroidal effusion (with choroids touching in the center of the eye, without blood) 
xChoroidal effusion (extending pos terior to equator, with blood)
xChoroidal effusion (obscuring disc or macula, with blood)
xChoroidal effusion (with chor oids touching in the center of the eye, with blood)
xChoroidal effusion and/or hemorrhag e occurring >30 days (persistent)
xChronic pain (present greater than 3 months)
xCorneal edema grade 3 or grade 4 (>30 days postoperatively)
xCyclodialysis
xDellen
xDevice malfunction
xEndophthalmitis
xFixed dilated pupil
xHyphema ( ¬ï2 mm in height [layered] at any time)
xHyphema (present or arising >30 days)
xHypotony (IOP <6 mm Hg at any time)
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 37 of 63
CONFIDENTIALxPersistent hypotony (IOP <6 mm Hg at 2 visits >30 days apart) 
xHypotony maculopathy
xImplant exposure
xImplant fracture
xImplant migration
xImplant obstruction (complete or partial)
xImplant repositioning requiring surgical intervention
xIncrease in cup/disc UDWLRRI¬ïXQLWV on slit lamp examination
x,QFUHDVHLQFRUQHDOWKL FNQHVVRI¬ïLQWKH presence of corneal edema
xIOP increase ¬ï 10 mm Hg from baseline
xIridodialysis
xIritis (requiring treatment after the postoperative medication taper)
xLoss of eye
xMacular edema
xMacular puckering
xPosterior capsule opacification
xPtosis
xRetinal complications
xSecondary surgical intervention
oExplant
oSecondary glaucoma procedure with explant
oSecondary glaucoma procedure
xSignificant (2-grade) worsening or a grade of moderate or severe, for any slitlamp observation for which a standard gr ading scale is not available (>30 days
postoperatively)
oAnterior chamber cells
oBlepharitis
oChalazion
oDysesthetic bleb
oHyperemia
xSignificant iris injury or atrophy
xStrabismus
xSuture abscess or other local infection
xVitreous hemorrhage
xVitreous loss
xWound leak/dehiscence
Assessment of Severity
Severity is a clinical determination of the intensity of an AE. The severity assessment 
for a clinical AE will be assigned a category by [CONTACT_3470]:
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 38 of 63
CONFIDENTIALMild: An AE that is easily tolerated by [CONTACT_423], causes minimal discomfort,
may require only minimal treatment and does not interfere with everyday 
activities.
Moderate: An AE that is sufficiently discomforting to interfere with normal 
everyday activities; intervention may be needed, but poses no significant 
or permanent risk of harm. 
Severe: An AE that prevents normal everyday activities; treatment or other 
intervention usually needed.
If there is a change in severity of an AE, it must be recorded as a separate event.
Assessment of Causality
Relationship to a device refers  to a determination of the relationship (if any) between an 
AE and the device. A causal relationship is pr esent if the investigator determines that 
there is a reasonable possibility that the AE may have been caused by [CONTACT_8121].
An AE could be considered procedure-related when, in the judgment of the investigator, 
it is reasonable to believe that the event is associated with the procedure, regardless of 
the relationship to the study device. Procedur e-related causes that contribute to the 
occurrence of the event can be attributed to other products, surgical techniques, or 
medications required specif ically for the procedure.
Every effort will be made by [CONTACT_63398], if any, to the device and/or study procedure. Caus ality should be assesse d using the categories 
presented in the following table:
Not related: Clinical event of which the relationship to the device and/or 
procedure can be excluded, such as if the event is incompatible time 
relationship to study procedure and/or use of the device, involves a 
body part or organ not expected to  be affected by [CONTACT_148540], could be explained by [CONTACT_148541], and is not due to use error. 
Unlikely: Clinical event whose time relationship to use of the device and/or
study procedure makes a causal conn ection improbable, but that could 
plausibly be explained by [CONTACT_148542].
Possible: Clinical event with a reasonable time relationship to the use of the 
device and/or study procedure, but that could also be explained by [CONTACT_148543] s or chemicals. Cases in which
relatedness cannot be a ssessed or no information has been obtained 
should also be classified as possible. 
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 39 of 63
CONFIDENTIALProbable: Clinical event with a reasonable time relationship to the use of the 
device and/or study procedure, and is  unlikely to be attributed to 
concurrent disease or other drugs or chemicals.
Causal 
relationship:Clinical event with plausible time relationship to the use of the device and/or study procedure, is a known side effect of the product category the device belongs to or of similar devices and procedures; follows a known response pattern to the medical  device; involves a body-site or 
organ that the device or procedures are applied to and/or influence;harm is due to error in use, and that cannot be explained by 
[CONTACT_9153].
Follow-up of Adverse Events
All investigators should follow up subjects with  AEs until the event is resolved or until, 
in the opi[INVESTIGATOR_871], the event is stabilized or determined to be chronic. 
Details of AE resolution must  be documented in the eCRF.
[IP_ADDRESS].3 Serious Ad verse Events
Serious Adverse Event Definition
An AE is considered an SAE if it:
a) led to death,b) led to serious deterioration in the hea lth of the subject, that either resulted in
1) a life-threatening illness or injury, or2) a permanent impairment of a body structure or a body function, or3) in-patient or prol onged hospi[INVESTIGATOR_059], or
4) medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function,
c) led to fetal distress, fetal death or a congenital abnormality or birth defect.
Note: Planned hospi[INVESTIGATOR_272] a pre-existing condition, or a procedure required by [CONTACT_760], without serious  deterioration in health, is not considered an SAE.
Serious Adverse Device Effect (SADE)
An SADE is an adverse device effect that  has resulted in any of the consequences 
characteristic of an SAE.
Reporting of Serious Adverse Events
All device- or surgery-related SAEs must be entered into the EDC system within
24 hours of being notified of the event. The sponsor will be notified by [CONTACT_148544].
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 40 of 63
CONFIDENTIALThe relationship of the clinical event to t he devices and procedure should be reported
on the Serious Adverse Event Form for Devices and will be determined by [CONTACT_31035].
Following evaluation of each SAE, the responsible IEC/IRB will be notified as 
appropriate based on na tional regulations.
All SAEs that occur from the time the informed consent form (ICF) is signed through to their final study visit must be reported to  the sponsor. In addition to entering the 
information into the EDC system, the investigator must:
xNotify the sponsor immediately (within 24 hours) by [CONTACT_148545]. The fo rm should be sent directly to the 
sponsor at [EMAIL_3038] or fax to +[PHONE_3310] or 
+[PHONE_3311]. The SAE report should be completed regardless of the 
amount of information available although th e investigator is expected to provide 
as much information as possible.
xObtain and maintain in his/her files all pertinent me dical records, information, 
and medical judgments from colleagues who assisted in the treatment and
follow-up of the subject.
xProvide the sponsor with a complete , written case history (AE report form) 
which includes a statement as to whether the event was or was not related to the 
use of the investigational device or procedure.
The sponsor (or its representative) will report all SAEs associated with the use of the 
study device to the regulatory agencies (IEC/IRB, Competent Authorities) as 
appropriate according to rele vant SOPs and to the nationa l laws of the country where 
the trial is performed.
For every SAE, appropriate measures should b e taken to treat/resolve and monitor the
subject. The investigator should keep Alle rgan closely informed of the progress as
related to the SAE. Any subjects who are wit hdrawn from the study due to an AE shall
still be followed up until the outcome is resolved.
10.[ADDRESS_170656]
Not applicable
10.2.1 Appropriateness of Measurements
The effectiveness and safety assessments pla nned for this study are widely used and 
generally recognized as reliable, accura te and relevant to the disease condition.
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 41 of 63
CONFIDENTIAL11 STATISTICAL METHODS
Prior to database lock a statistical analysis plan (SAP) defining all details of analysis 
will be prepared and finalized.
11.1.[ADDRESS_170657] has signed the 
ICF. The Enrolled population will be used to summarize disposition data.
The Intent-to-treat (ITT) population consists of all enrolled eyes randomized to study 
glaucoma surgery (XEN or trabeculectomy) . The ITT population will be the primary 
analysis population for effectiveness data. Subject demographics, baseline 
characteristics, and PRO data will be an alyzed using the ITT population. Subjects will 
be grouped and analyzed according to the actual surgery received.
The Modified Intent-to-treat (mITT) populati on consists of eyes in the ITT population 
that receive study glaucoma surgery and ha ve no major protocol deviations, which will 
be defined in the SAP and identified prior to database lock. The  mITT population will 
be used for selected effectiveness endpoints (a s specified in the SA P), and will be used 
for the analyses of PRO data also.
The Safety population consists of all en rolled eyes that undergo study glaucoma 
surgery, whether surgery is completed or  aborted, and have follow-up visits or 
evaluations. The Safety population will be used to analyze AEs, medical and ophthalmic 
history, and concomitant me dications (ocular and systemic). Subjects will be grouped 
and analyzed according to the surgery they received.
11.1.[ADDRESS_170658] characteristics will be summarized. Descriptive 
statistics (such as mean, SD, minimum, medi an, and maximum) will be presented for 
each continuous variable. Categorical vari ables will be displayed using frequency 
counts and percentages.
11.1.3 Effectiveness Variables and Statistical Analyses 
Definition of Primary Effectiveness Endpoint
The primary endpoint for the study will be the percentage of subjects achievin J¬ï
mean IOP reduction from baseline at Month 12 on the same or fewer number of topi[INVESTIGATOR_148518]-lowering medications, without clinical hy potony, loss of vision to count fingers, or 
secondary glaucoma surgical intervention.
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 42 of 63
CONFIDENTIALDefinition of Secondary Effectiveness Endpoints
Effectiveness will be determined by [CONTACT_148546] 12, and the number of topi[INVESTIGATOR_15434]-lowering medications at 
screening with number of topi[INVESTIGATOR_15434]-lowe ring medications at Month 12. Individual 
secondary effectiveness endpoints are defined in Section 7.2 .
Definition of Performance Endpoints (Device Studies)
The IOP change at all visit windows will be summarized by [CONTACT_8477], SD, median, 
maximum, and minimum. The percentage chan ge in IOP from baseline to Month 12
will also be summarized descriptively. When necessary, appropriate parametric or 
nonparametric analyses will be used to dete rmine statistically significant differences.
Methods of Statistical Analysis
The number and proportion of subjects DFKLHYLQJ¬ïPHDQ,23UHGXFWLRQIURP
baseline at Month 12 on the same or fe wer number of topi[INVESTIGATOR_15434]-lowering 
medications, without clinical hypotony, loss of vision to count fingers, or secondary 
glaucoma surgical intervention will be tabulated with 95% CI calculated by [CONTACT_148547]. The difference of  the proportions will be estimated and 
the 95% CI of the difference will also be calculated with the method of the normal 
approximation. The 2 treatment groups will be claimed as equi valent if the 95% CI of 
the differences is within the -18% to 18% interval. The least squares mean change from 
baseline in IOP and the least squares mean difference between the 2 treatment groups
will be estimated using the analysis of covariance (ANCOVA) model or the mixed-
effect model repeat measurement (MMR M) model. The proportion and 95% CI of 
complete success and qualified success will be calculated with normal approximation.
11.1.4 Safety Variables
All reported treatment-emergent AEs (TEAEs), treatment-related TEAEs, SAEs, and all 
safety measures collected will be tabulated by [CONTACT_33335]. Adverse events will be summarized by [CONTACT_148548]. Any other information collected (such as AE severity) will be tabulated and listed as appropriate. Pregnancy of female subjec ts should also be tabulated. Analyses of AEs 
and other safety variables will be described in the SAP.
11.1.[ADDRESS_170659] reported significantly high 
treatment success rates. Grove r et al. reported 75.4% of the treated patients having 
achieved success, as defined by a >20% re duction from baseline in IOP at Month 12 on 
the same or fewer medications ( Grover et al. 2017 ). Mansouri et al. reported 81% 
success rate at Month 12, and Tan et al. ( 2018) reported success rates of 87% and 92% 
at Month 12 depending on if pa tients were using medications ( Mansouri et al. 2018, Tan 
et al. 2018 ). However, it should be noted that th e 3 studies are based on relatively small 
sample sizes in the XEN alone arm, rangin g from 21 to 61 evaluable study eyes, and a 
more conservative estimate of the succe ss rate is about 70%. A previous study 
supported that the XEN procedure and the stan dard of care therapy trabeculectomy are 
comparable in terms of treatment success ( Schlenker et al. 2017). Moreover, it is 
assumed that neither treatment is better or worse than the other by [CONTACT_726] 20% in 
terms of treatment success rate. This trial is intended to demonstrate that XEN is comparable to trabeculectomy in terms of treatment success rate. The sample size calculation is based on an equivalence test.
To control Type-I error rate at 5% and to attain 80% power for demonstrating that the 
difference is within the equivalence limit of  18%, about 256 study eyes will be needed 
for the study with a randomization ratio of 2:1 for the XEN arm: trabeculectomy arm.Allowing a 10% dropout rate for the first year, approximately 285 study eyes (190 for 
the XEN arm and 95 for the trabeculectomy arm) will need to be recruited for the study.
11.[ADDRESS_170660] be in formed as soon as possible. 
Protocol deviations and/or violations and the reasons they occurred will be included in 
the clinical study report. Reporting of pr otocol deviations to the IRB/IEC and in 
accordance with applicable regulatory authority mandates is an investigator‚Äôsresponsibility.
Allergan [ADDRESS_170661] data will be reviewed and/or audited, and all deficiencies corrected on site, if possible. A complete report will be made of all monitoring visits. If the study is terminated, a study close-out visit may be scheduled with the site if needed to retrieve all remaining study records.
The monitor will review the study conduct to determine compliance with the study 
protocol and GCP guidelines. The monitor will review and/or audit the electronic forms and source documents to ensure the accuracy and completeness of the data captured for 
the study. The monitor will review the subject ICFs to ensure that no forms were signed prior to the date of IEC/IRB approval of the study. The system for record-keepi[INVESTIGATOR_148519].
12.[ADDRESS_170662] source 
documents at the study center. Data to be recorded directly on the eCRF will be identified and the eCRF will be considered the source document. Any changes to the data entered into the EDC system will be recorded in the audit trail and will be compliant with FDA CFR 21 Part 11. PRO data will not require source documentation.
Medical coding will use Medical Dictionary for Regulatory Activities (MedDRA) for 
concomitant diseases and AEs, and World Health Organization (WHO) Drug Dictionary for medications. Secondary surgical pr ocedures and intra- and postoperative 
complications will be captured by [CONTACT_148549] (not upper-level terms).
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 45 of 63
CONFIDENTIALMissing or inconsistent data will be queried in writing to the investigator for 
clarification. Subsequent modifications to the database will be documented.
12.4 Quality Management and Risk Evaluation
Details are provided in Section 8.2.2.
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 46 of 63
CONFIDENTIAL13 RECORDS AND SUPPLIES
13.1 Device Accountability
If devices are not supplied to the site, this section does not apply.
If devices are supplied to the site, on receip t of the study device, the investigator (or 
deputy) will conduct an inventory of the supplies and verify that study device supplies 
are received intact and in the correct am ounts before completing a supplies receipt. The 
investigator will retain a copy of this receipt at the study center. The monitor may check the study supplies at each study center at any time during the study.
13.[ADDRESS_170663]
Before initiation of the study at each study center, the protocol, the ICF, other written 
material given to the subjects, and any other requested study documentation will be submitted to the appropriate IEC/IRB. Written approval of the study and all relevant study information must be obtained before the study center can be initiated. Any necessary extensions or renewals of IEC/IR B approval must be obtained for changes to 
the study such as amendments to the protocol, the ICF, or other study documentation. The written approval of the IEC/IRB together with the approved ICF must be filed in the study files.
The investigator will report promptly to the IEC/IRB any new information that may 
adversely affect the safety of the subjects or  the conduct of the study. The investigator 
will submit written summaries of the study status to the IEC/IRB as required. On completion of the study, the IEC/IRB will be notified that the study has ended.
14.[ADDRESS_170664] of the Study
The investigator(s) and all parties involved in this study should conduct the study in 
adherence to the ethical principles based on the Declaration of Helsinki, GCP, ICH 
guidelines, ISO [ZIP_CODE]:2011, and the applicable national and local laws and regulatory 
requirements.
14.[ADDRESS_170665] be in accordance with applicable 
regulatory requirement(s) and must adhere to GCP.
The investigator is responsibl e for ensuring that no subject undergoes any study-related 
examination or activity before that subject has given written informed consent to 
participate in the study.
The investigator or designated personnel will inform the subject of the objectives, 
methods, anticipated benefits, and potential ri sks and inconveniences of the study. The 
subject should be given every opportunity to as k for clarification of any points s/he does 
not understand and, if necessary, ask for more information. At the end of the interview, the subject will be given ample time to consider the study. Subjects will be required to sign and date the ICF. After signatures are obtained, the ICF will be kept and archived 
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 48 of 63
CONFIDENTIALby [CONTACT_41798]‚Äôs study file. A signed and dated copy of the 
subject‚Äôs ICF will be provided to the subject or their authorized representative.
It should be emphasized that the subject may refuse to enter the study or to withdraw 
from the study at any time, without consequences  for their further care or penalty or loss 
of benefits to which the subject is otherwise entitled. Subjects who refuse to give or who 
withdraw written informed consent should not  be included or continue in the study.
If new information becomes available that may be relevant to the subject‚Äôs willingness to continue participation in the study, a new ICF will be approved by [CONTACT_6179](s)/IRB(s) (and regulatory authorities, if required). The study subjects will be informed about this 
new information and reconsent will be obtained.
14.[ADDRESS_170666] Confidentiality
Monitors, auditors, and other authorized agen ts of the sponsor and/or its designee, the 
IEC(s)/IRB(s) approving this research, and th e US FDA, as well as that of any other 
applicable agency(ies), will be granted di rect access to the study subjects‚Äô original 
medical records for verification of clinical  study procedures and/or data, without 
violating the confidentiality of the subjects to the extent permitted by [CONTACT_99437]. In any presentations of the resu lts of this study or in publications, the 
subjects‚Äô identity will remain confidential.
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 49 of 63
CONFIDENTIAL15 REPORTING AND PUBLICATION, INCLUDING ARCHIVING
Essential documents are those documents that individually and collectively permit 
evaluation of the study and quality of the da ta produced. After completion of the study
(end of study defined as the date of the last visit of the last subject), all documents and 
data relating to the study will be kept in an orderly manner by [CONTACT_9916] a secure study file. This file will be availa ble for inspection by [CONTACT_148550]. Essential documents should be retained for [ADDRESS_170667] the sponsor 
before destroying any study-related documentation. In addition, all subjects‚Äô medical records and other source documentation will be kept for the maximum time permitted by [CONTACT_5035][INVESTIGATOR_307], institution, or medical practice.
Data from individual study centers in this multicenter study may not be published 
separately.
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 50 of 63
CONFIDENTIAL16 REFERENCES
American Academy of Ophthalmology (AAO) Glaucoma Preferred Practice Pattern¬Æ 
(PPP) Panel. Primary open-angle glaucoma Preferred Practice Pattern. San Francisco: American Academy of Ophthalmology; 2006. Available from: https://www.aao.org/ preferred-practice-pattern/p rimary-open-angle-glaucoma-ppp-2015. Accessed 07 Mar 
2019.
Aref AA, Varma R. Advanced glaucoma surgery, essentials in ophthalmology.
Switzerland: Springer; 2012
Azuara-Blanco A, Katz LJ. Dysfunctional filtering blebs. Surv Ophthalmol. 
1998;43:93-126.
Baudouin C. Ocular surface and external filtra tion surgery: mutual relationships. Dev 
Ophthalmol. 2012;50:64-78.
Caprioli J, Kim JH, Friedman DS, Kiang T, Moster MR, Parrish RK 2
nd, et al. Special 
commentary: supporting innovation for safe and effective minimally invasive glaucoma 
surgery: summary of a joint meeting of th e American Glaucoma Society and the Food 
and Drug Administration, Washington, DC, February 26, 2014. Ophthalmology.
2015;122:1795-1801.
De Gregorio A, Pedrotti E, Russo L, Morselli S. Minimally invasive combined 
glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent. IntOphthalmol. 2018 Jun;38:1129-1134.
Fechtner RD, Singh K. Maximal glaucoma therapy. J Glaucoma. [ADDRESS_170668];10([ADDRESS_170669] 
1):S73-S75.
Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC. Surgical 
complications in the Tube Versus Trabeculect omy Study during the first year of follow-
up. Am J Ophthalmol. 2007 Jan;143:23-31.
Gedde SJ, Heuer DK, Parrish RK 2nd; T ube Versus Trabeculectomy Study Group. 
Review of results from the Tube Versus Tr abeculectomy Study. Curr Opin Ophthalmol. 
2010 Mar;21:123-128.
Gedde SJ, Schiffman JC, Feuer WJ, Her ndon LW, Brandt JD, Budenz DL, et al. 
Treatment outcomes in the Tube Versus Trab eculectomy (TVT) study after five years of 
follow-up. Am J Ophthalmol. 2012 May;153:789-803.
Allergan [ADDRESS_170670] K, Lewis R, Duh YJ, Nangia RS, et al. Performance and 
safety of a new ab interno gelatin stent in refractory glaucoma at 12 months. Am J Ophthalmol. 2017;183:25-36.
Hengerer FH, Kohnen T, Mueller M, Conrad-H engerer I. Ab interno gel implant for the 
treatment of glaucoma patients with or without prior glaucoma surgery: 1-year results. J 
Glaucoma. 2017 Dec;26:1130-1136.Mansouri K, Guidotti J, Rao HL, Ouabas A, D'Alessandro E, Roy S, Mermoud A.
Prospective evaluation of standalone XEN Gel Implant and combined phacoemulsification-XEN Gel Implant surg ery: 1-year results. J Glaucoma. 2018 
Feb;27:140-147.
Moisseiev E, Zunz E, Tzur R, Kurtz S, Shemesh G. Standard trabeculectomy and Ex-
PRESS Miniature Glaucoma Shunt: a compa rative study and literature review. J
Glaucoma. 2015 Aug;24:410-416.
Musch DC, Tarver ME, Goren MJ, Janz NK. Development of an 18-Item measure of 
symptom burden in patients with glaucoma from the Collaborative Initial Glaucoma 
Treatment Study's Symptom and Health Problem Check list. JAMA Ophthalmol. 2017
Dec 1;135:1345-1351.
Quigley HA. Number of people with gl aucoma worldwide. Br J Ophthalmol.
1996;80:389-393.
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work 
productivity and activity impairment inst rument. Pharmacoeconomics. 1993;4:363-365.
Reitsamer HA. Translimbal collage implant. Aquesys XEN Gel Stent. In: Francis BA, Sarkisian SR, Tad JC (eds): Minimally invasive glaucoma surgery. Stuttgart: Thieme;2016.
Rulli E, Biagioli E, Riva I, Gambirasio G, De Simone I, Floriani I, et al. Efficacy and 
safety of trabeculectomy vs nonpenetrating surg ical procedures: a systematic review and 
meta-analysis. JAMA O phthalmol. 2013 Dec;131:1573-1582.
Saheb H, Ahmed II. Micro-invasi ve glaucoma surgery: current perspectives and future 
directions, Curr Opin Ophthalmol. 2012;23:96-104.
Schlenker MB, Gulamhusein H, Conrad-Hengere r I, Somers A, Lenzhofer M, Stalmans 
I, et al. Efficacy, safety, and risk factors for failure of standalone ab interno gelatin 
microstent implantation ve rsus standalone trabeculectomy. Ophthalmology. 2017 
Nov;124:1579-1588.
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 52 of 63
CONFIDENTIALShaarawy T, Flammer J, Haefliger IO. Reducin g intraocular pressure: is surgery better 
than drugs? Eye (Lond). 2004;18:1215-1224.
Sheybani A, Reitsamer H, Ahmed II. Fluid  dynamics of a novel micro-fistula implant 
for the surgical treatment of glauco ma. Invest Ophthalmol Vis Sci. 2015;56:4789-4795.
Tan SZ, Walkden A, Au L. One-year result of XEN45 implant for glaucoma: efficacy, 
safety, and postoperative manage ment. Eye (Lond). 2018 Feb;32:324-332.
Vera V, Ahmed IIK, Stalmans I, Retisamer H. Gel stent implantation-recommendations for preoperative assessment, surgical tec hnique, and postoperative management. US 
Ophthalmic Rev. 2018;11:38-46.
Vijaya L, Manish P, Ronnie G, Shantha B. Management of complications in glaucoma 
surgery. Indian J Ophthalmol. 2011 Jan;[ADDRESS_170671]:S131-140.
Wang S, Gao X, Quan N. The Ahmed shunt ve rsus the Baerveldt shunt for refractory
glaucoma: a meta-analysis. BMC Ophthalmol. 2016 Jun 8;16:83.
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 53 of 63
CONFIDENTIAL17 APPENDICES
17.1 The SHPC-18 Questionnaire
Protocol Title:  XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma:  
Gold-Standard Pathway Study (GPS) 
Site Number   XX Subject Number  XXX   Date (DD-MMM-YYYY):      - -
VISIT:  Screening  [ADDRESS_170672] 7 days. If you 
answer ‚ÄúYes‚Äù to any of these symptoms or problems, please also answer a follow-upquestion about how much these sy mptoms or problems bother you.
Local Eye      
Symptoms 
Have you had this symptom  
in the past 7 days? If Yes, please rate how much you fee
the symptom is due to your  
glaucoma or its treatment ,I‚Äú<HV‚ÄùKRZPXFKKDVWKLV
SUREOHPERWKHUHG\RX" 
1.   
Eye irritation 
or burning«πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat 
‡∂¥ A Moderate Amount 
‡∂¥ A Lot
2.    Feeling like 
something is 
in your eye(s)
 «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat  
‡∂¥ A Moderate Amount 
  ‡∂¥ A Lot
3.    Droopy eyelids  «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat 
‡∂¥ A Moderate Amount 
  ‡∂¥ A Lot

Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 54 of 63
CONFIDENTIALLocal Eye      
Symptoms 
Have you had this symptom  
in the past 7 days? If Yes, please rate how much you fee
the symptom is due to your  
glaucoma or its treatment ,I‚Äú<HV‚ÄùKRZPXFKKDVWKLV
SUREOHPERWKHUHG\RX" 
4.    
Excessive 
tearing  «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat 
‡∂¥ A Moderate Amount 
  ‡∂¥ A Lot
5.    
Skin 
sensitivity 
around your eye(s)
 «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat  
‡∂¥ A Moderate Amount 
  ‡∂¥ A Lot
6.    
Eye pain  «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat 
‡∂¥ A Moderate Amount 
 ‡∂¥ A Lot
7.    
Red eyes  «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat 
‡∂¥ A Moderate Amount 
  ‡∂¥ A Lot
 
9LVXDO)XQFWLRQ
3UREOHPV Have you had this symptom  
in the past 7 days? ,I<HVSOHDVHUDWHKRZPXFK
\RXIHHOWKHV\PSWRPLVGXH
WR\RXUJODXFRPDRULWV
WUHDWPHQ W,I‚Äú<HV‚ÄùKRZPXFKKDV
WKLVSUREOHPERWKHUHG
\RX"
1.    
Difficulty 
with distant 
vision  «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat 
‡∂¥ A Moderate Amount  
«πA Lot
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 55 of 63
CONFIDENTIAL9LVXDO)XQFWLRQ
3UREOHPV Have you had this symptom  
in the past 7 days? ,I<HVSOHDVHUDWHKRZPXFK
\RXIHHOWKHV\PSWRPLVGXH
WR\RXUJODXFRPDRULWV
WUHDWPHQ W,I‚Äú<HV‚ÄùKRZPXFKKDV
WKLVSUREOHPERWKHUHG
\RX"
2.    
Difficulty 
with near 
vision  «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat 
‡∂¥ A Moderate Amount  
«π A Lot
3.    
Changes in 
depth 
perception  «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat 
‡∂¥ A Moderate Amount  
«πA Lot
4.   
Distortion in 
vision  «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat 
‡∂¥ A Moderate Amount  
«πA Lot
5.    
Dimming of 
vision  «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat 
‡∂¥ A Moderate Amount  
«πA Lot
6.    
Trouble 
with color 
vision  «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat 
‡∂¥ A Moderate Amount  
«πA Lot
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 56 of 63
CONFIDENTIAL9LVXDO)XQFWLRQ
3UREOHPV Have you had this symptom  
in the past 7 days? ,I<HVSOHDVHUDWHKRZPXFK
\RXIHHOWKHV\PSWRPLVGXH
WR\RXUJODXFRPDRULWV
WUHDWPHQ W,I‚Äú<HV‚ÄùKRZPXFKKDV
WKLVSUREOHPERWKHUHG
\RX"
7.    
Blurry vision  «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat 
‡∂¥ A Moderate Amount  
«πA Lot
8.    Difficulty with light transition (e.g., from bright to dark) «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes  «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat 
‡∂¥ A Moderate Amount  
‡∂¥ A Lot  
9.    
Difficulty seeing in dark places «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat 
‡∂¥ A Moderate Amount  
‡∂¥ A Lot  
10.  
Difficulty 
with bright lights «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat 
‡∂¥ A Moderate Amount  
‡∂¥ A Lot  
11.  
Difficulty 
seeing when 
steppi[INVESTIGATOR_148520] «πNo 
«πYes: which eye(s) is/are 
affected? 
«πSurgery eye 
«πOther eye 
«πBoth eyes «πEntirely due 
«πPartially due 
«πNot due ‡∂¥ Not at All  
‡∂¥ A Little 
‡∂¥ Somewhat 
‡∂¥ A Moderate Amount  
‡∂¥ A Lot  
 
Allergan [ADDRESS_170673] resumed your usual 
activities and daily routine?
____  Not at all ____ Somewhat   ___ Moderately so ____  Mostly  ___ Completely
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 58 of 63
CONFIDENTIAL17.3 Work Productivity and Activity Impairment Questionnaire
Work Productivity and Activity Impairment Questionnaire:
General Health V2.0 (WPAI:GH)
The following questions ask about the effect of your health problems on your ability to 
work and perform regular activities. By [CONTACT_148551]. Please fill in the blanks or circle a number, as 
indicated.
1. Are you currently employed (working for pay)? ____  NO ____  YES
If NO, check ‚ÄúNO‚Äù and skip to question 6.
The next questions are about the past seven days , not including today.
2. During the past seven days, how many hours did you miss from work because of
your health problems? Include hours you missed on sick  days, times you went in 
late, left early, etc., because of your health problems. Do not include time you 
missed to participate in this study.
_____HOURS
3. During the past seven days, how many hours did you miss from work because of 
any other reason, such as vacation, holidays, time off to participate in this study?_____HOURS
4. During the past seven days, how many hours did you actually work?
_____HOURS (If ‚Äú0‚Äù, skip to question 6.)
Allergan [ADDRESS_170674] your 
productivity while you were working?
Think about days you were limited in the amount or kind of work you could do, 
days you accomplished less than you would like, or day s you could not do your 
work as carefully as usual. If health problems affected your work only a little, choose a low number. Choose a high number if health problems affected your work a great deal. 
Consider only how much health problems affected 
productivity while you were working.
Health problems had no effect on my workHealth problems completely prevented me from working0123456789 [ADDRESS_170675] your 
ability to do your regular daily activities, other than work at a job? 
By [CONTACT_43681],  we mean the usual activities you do, such as work around 
the house, shoppi[INVESTIGATOR_007], childcare, exercising, studying, etc. Think about times you 
were limited in the amount or kind of  activities you could do and times you 
accomplished less than you would like. If he alth problems affected your activities 
only a little, choose a low number. Choose a high number if health problems affected your activities a great deal. 
Consider only how much health problems affected your ability 
to do your regular daily activities, other than work at a job.
Health problems had no effect on my daily activitiesHealth problems completely prevented me from doing my daily activities01234567891 [ADDRESS_170676] of abbrevia tions and table of contents, reformatting and restyling of 
text (including the reference list and appe ndices), and changes in study team staff.
Specific revisions in verbatim text are shown in bold font in the changes listed below.
Version Date Description of Change (location) Rationale
1.[ADDRESS_170677] number (title page) Trial was registered on 
ClinicalTrials.gov on 31 Aug 2018
Updated name [CONTACT_148552] (title page, 
Section 12.3, and Section 13.2)INC Research merged with inVentive Health and is now doing 
business as Syneos Health
Added description of statistical analyses 
in the SynopsisCorrected an omission in the synopsis
Added objectives statement to Section 7) Added a missing objectives 
statement that matches the one in 
the synopsis
Added a secondary effectiveness 
objective: ‚ÄúMean and changes in mean 
IOP and number of topi[INVESTIGATOR_15434]-lowering 
medications from preoperative baseline over time in eyes with medicated baseline ,23¬î mm Hg‚Äù (Section 7.2
and Synopsis )Adds a subgroup analysis for study 
eyes with IOP in the lower part of the allowed IOP range (15 to 18 mm Hg) at preoperative baseline
Corrected timing of autorefractor measurements and biometry (Section 7.2
and Synopsis )Corrected mistakes in the text of the protocol to match the timing of these procedures in Table 8.1
Clarified study duration is per study eye 
(Section 8.1and Synopsis )Distinguishes duration for a studyeye versus overall study duration 
(ie, all study eyes)
Investigator will select the study eye if 
both eyes meet entry criteria (Section 8.1)Allows the investigator to make the decision
Clarified that [ADDRESS_170678] will be enrolled (Section 8.3.1 and Synopsis )Clarifies that only [ADDRESS_170679]‚Äôs eyes will be enrolled, even if both 
eyes meet entry criteria
Added visit windows to Table 8.1 ;
revised postoperative visit windows in Sections 9.1.2 and 9.2Provides a visit range for each 
postoperative study visit
Added randomization to Table 8.1 and the 
description of the Preoperative Visit (Section 9.1.2 )Specifies at which visit 
randomization occurred
Gonioscopy is required at the Baseline 
Qualifying Visit and is optional at Allows investigators to follow their standard of care for timing of 
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 61 of 63
CONFIDENTIALVersion Date Description of Change (location) Rationale
postoperative Visits 3, 4 and 10 
(Table 8.1 )postoperative gonioscopy
Removed AS-OCT at Visit 1 ( Table 8.1 ) Preoperative AS-OCT is not 
required.
Changed one of the listed risks of the 
XEN implantation procedure to be 
‚Äúunplanned secondary surgical 
intervention ‚Äù (Section 8.2.2)Corrected an error in the protocol 
(previously was ‚Äúunplanned 
surgical re-invention ‚Äù)
Increased the number of study sites to 
‚Äúapproximately 25 to 40 sites‚Äù
(Section 8.3.1 and Synopsis )Increase enrollment rate into the 
study to complete enrollment in a 
timely manner
Inclusion criterion 4. ‚ÄúBest-corrected 
baseline Snellen visual acuity of 20/ 100
or better‚Äù (Section 8.3.2 and Synopsis )Allows inclusion of study eyes with 
poorer vision in order to improve 
enrollment rate based on investigator feedback
Inclusion criterion 5. ‚ÄúVisual field mean 
deviation no worse than - 18.0 dB (with 
no dense paracentral scotomas, eg, 
>18dB total deviation on 1 or more of 
the 4 paracentral points)‚Äù (Section 8.3.2
and SynopsisAllows inclusion of study eyes with 
slightly more advanced visual field 
damage in order to improve enrollment rate based on investigator feedback
Inclusion criterion 6. ‚ÄúMedicated IOP ¬ï15PP+JDQG¬îPP+J on at least 
1topi[INVESTIGATOR_15434]-lowering medication‚Äù
(Section 8.3.2 and Synopsis )Allows study eyes with lower medicated IOP at baseline to 
improve enrollment rate based on 
investigator feedback. Clarifies thatmore than 1 IOP-lowering medication will be allowed.
Inclusion criterion 7. ‚ÄúSubjects not 
anticipated to require any other ocular 
surgery (eg, cataract surgery) in either eye up to 3 months from the time of 
inclusion‚Äù (Section 8.3.2 and Synopsis)Allows inclusion of study eyes that 
may require ocular surgery during 
the 12-month study, provided the surgery occurs at least 3 months after enrollment
Inclusion criterion 9. ‚ÄúVisible trabecular PHVKZRUNZLWK6KDIIHUDQJOHJUDGH¬ïLQthe target area or, in eyes with prior 
failed angle surgery, an open angle in 
the target area ‚Äù (Section 8.3.2
and Synopsis )Clarification that the angle is open 
in eyes that have had angle surgery,such as GATT
Inclusion criterion 10. ‚ÄúPreoperative laser 
trabeculoplasty is allowed 3 or more 
months prior to randomization‚Äù
(Section 8.3.2 and Synopsis )Corrects an error in the allowed 
period for laser trabeculoplasty
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 62 of 63
CONFIDENTIALVersion Date Description of Change (location) Rationale
Inclusion criterion 11. ‚ÄúFailed ab-interno 
canal or suprachoroidal microinvasive 
glaucoma surgery ( MIGS )procedures 
(such as iStent¬Æ,gonioscopy-assisted 
transluminal trabeculotomy [ GATT ],
ab-interno canaloplasty [ ABiC ‚Ñ¢],
Kahook Dual Blade goniotomy, etc) are 
allowed 3 or more months before 
enrollment , with the exception of 
CyPass¬Æ Micro-Stent s, which are not 
allowed. Ab-interno ablative 
procedures (such as endoscopic cyclophotocoagulatio n [ECP]) are also 
allowed 3 or more months before 
enrollment. ‚Äù (Section 8.3.2
and Synopsis )Excludes CyPass Micro-Stents, 
which have been withdrawn from 
the market
Distinguishes ab-interno ablative 
procedures, such as ECP which is 
allowed, from transscleral 
cycloablative procedures that are 
excluded per exclusion criterion 2
Exclusion criterion 16. ‚ÄúParticipation in 
another drug or device clinical trial that
conclud eswithin 30 days before the 
Preoperative Visit or that starts at any 
time during this study ‚Äù (Section 8.3.3
and Synopsis )Prohibits concurrent participation in another drug or device clinical trial
Added ‚ÄúSubjects may withdraw their 
consent to continue in the study at any 
time.‚Äù (Section 8.3.4 )Clarifies that subjects will be free 
to withdraw consent at any time
Added ‚ÄúSubjects who discontinue before undergoing a study surgery will not be 
required to return for study follow-up visits‚Äù (Section 8.3.4 ) and updated 
Section 9.2.[ADDRESS_170680] name (XEN-45
Gel Stent) (Section 8.4.2 )Clarified XEN implant lumen size
Added a description of the randomization 
process (Section 8.4.4 )Adds information that was missing from the protocol
Clarified that IOP will not be measured at 
Visit 2 (Section [IP_ADDRESS] )Corrected the text to match Table 8.1
Added that the PRO questionnaires will be administered using an electronic tablet, 
from which data will be imported into the eCRF (Section [IP_ADDRESS] )Clarifies that PRO data will be 
entered externally in an electronic 
tablet and then imported into the eCRF electronically (ie, data will not be entered manually into the 
PRO eCRFs)
Added ‚Äú These and any other AEs that 
occur should be reported in the AE 
eCRF .‚Äù to Section [IP_ADDRESS].2 )Clarifies that all AEs, in addition to 
the listed possible intraoperative 
and postoperative AEs are to be 
reported in the AE eCRF
Allergan 21 Mar 2019
CMO-US-EYE-0600 Version 2.0 Page 63 of 63
CONFIDENTIALVersion Date Description of Change (location) Rationale
Revised the worsening cataract AE to 
‚ÄúClinically significant progression of 
cataract , based on an assessment by [CONTACT_1275] ‚Äù (Section [IP_ADDRESS].2 )Removed mention of Lens Opacities Classification System scoring because it will not be used in this study
Added Enrolled and mITT populations as analysis populations; updated definitions 
of ITT and Safety populations 
(Section 11.1.1 )Adds an Enrolled population to 
fully describe disposition of study eyes. Adds an analysis population 
(mITT) that excludes study eyes 
that do not undergo glaucoma surgery or have predefined major protocol deviations. Adds detail on which populations are used for study analyses.
Removed statement that all available IOP 
data will be used for calculations of 
changes from baseline, and added some 
statistical methodology (Section 11.1.3,
latter in Synopsis , too)Selection of IOP values for change 
from baseline calculations will be described in the SAP, as it will be 
based on timing of IOP 
measurements relative to the visits. 
Briefly describes statistical testing that was missing.
Clarified that treatment-emergent AEs 
will be summarized and added details on 
some types of tabulations that are planned (Section 11.1.4 and Synopsis )Clarifies that any AEs that occur before study surgery will not be included in AE summary tables. Cross-references the SAP for more 
details on safety analyses.
Revised ‚ÄúIOP, change in IOP from 
baseline, percentage change in IOP from 
baseline, number of topi[INVESTIGATOR_15434]-
lowering medications used, and change 
in number of topi[INVESTIGATOR_15434]-lowering
medications used will be summarized 
descriptively at each scheduled visit.‚Äù(Section 11.1.6 )Clarified that the analysis will be of number of topi[INVESTIGATOR_15434]-lowering 
medications
Deleted from the reference list those 
references not cited in the text (Section 16)Corrected an error in the protocol
Increased row height in SHPC-18
questionnaire (Appendix 17.1 )Makes ‚ÄúBoth eyes‚Äù checkboxes visible in all rows
Added protocol revision history (Appendix 17.4)Adds a section to describe changes made in the protocol since the 
original version was approved
Added expansion of abbreviations and acronyms on first use in the synopsis and main text; used abbreviation/acronym 
thereafterStandardizes use of abbreviations 
and acronyms